תדריך לעריכת קורות חיים...
TRANSCRIPT
1
Name: Dr. Shira Zelber-Sagi Date: February 2012
CURRICULUM VITAE
1. Personal Details
Name: Shira Zelber-Sagi
Date of Birth: March 9, 1974
Country of Birth: Israel
Identity Card Number: 02728738-2
Marital Status: Married and mother to Tom and Idan
Permanent Home Address: 5 Mosinson St. Tel Aviv 62965, Israel
Home Telephone Number: Tel: 972-3-5446086
Office Telephone Number: Tel: 972-3-5446086
Electronic Address: [email protected]
Fax Number: Tel: 972-3-5446086
2
2. Higher Education
A. Under graduate and Graduate Studies
Date of
Degree
Degree Name of Institution
and Department
Period of
Study
Sep 98 B.Sc Nutrition Sciences in the Agriculture Faculty,
Hebrew University
1995-
1998
August 07 Ph.D
Direct
course
Epidemiology and Preventive
Medicine, Sackler School of
Medicine, Tel Aviv University
2001-
2007
B. Post-Doctoral Studies
Since the graduation of the Ph.D I have been collaborating with senior
researchers from Israel and abroad. I have an ongoing cooperation with
two hospitals (besides the Tel-Aviv Sourasky Medical Center). The first
is with Prof Vlad Ratziu from Université Pierre et Marie Curie, Hôpital
Pitié Salpêtrière, Paris France in the subject of non-invasive assessment
of liver damage by biomarkers and the association with adipocytokines
in patients with fatty liver – a paper have been submitted. We also
compare different non-invasive methods for liver steatosis – the results
were presented in a conference by the European association for the study
of the liver and the paper is under preparation. Prof Ratziu and I also
wrote two literature reviews: one has been published and the seconds is
in print. I also have cooperation with Dr. Assy Nimer, Head, Liver
Clinic at Ziv Medical Center and Senior Lecturer at the Faculty of
Medicine, Technion Institute. I have initiated a clinical trial on the effect
of soft drinks in patients with fatty liver, which is ongoing.
3
3. Academic Ranks and Tenure in Institutes of Higher Education
2009- Lecturer at the School of Public Health, Faculty of Social Welfare and
Health Sciences, University of Haifa
4. Offices in University Academic Administration
*Responsible for research committee at the School of Public Health, Faculty of
Social Welfare and Health Sciences, University of Haifa.
5. Scholarly Positions and Activities outside the University
a. Professional Experience -
1999- Dietitian and Group manager. Sourasky Medical Center and Clalit Health
Services.
1999-2001- Manager of the nutrition field in "Mishan" Givataim geriatric
institute.
2006-07- Manager of internet nutrition forum for Clalit Health Services.
2009-2010 – Researcher responsible for the construction of a long term health
promotion program tailored for low socioeconomic population. The Samuel
Neaman Institute, the Technion.
b. Membership in professional associations
2000-2010 - The Israeli nutrition Association – ATID.
2002-2010 - The Israeli Association for the Study of the Liver.
2010 – The European Association for the Study of the Liver.
4
6. Participation in Scholarly Conferences
a. Active Participation
Subject of
Lecture/Discussion/Comments
Place of
Conference
Name of
Conference
Date No.
International Conferences
The prevalence of primary
nonalcoholic fatty liver disease
in the Israeli population and the
association with biochemical
and anthropometric measures.
Lisbon European
Association for the
Study of the Liver
09/04 1.
A double-blind randomized
placebo-controlled trial of
Orlistat for the treatment of
nonalcoholic fatty liver disease.
Boston American
Association for the
Study of Liver
Diseases
10/04 2.
Does weight loss improve liver
histopathology in nonalcoholic
fatty liver disease?
Paris European
Association for the
Study of the Liver
04/05
3.
Increased prevalence of
nonalcoholic fatty liver disease
in patients with acute
myocardial infarction
independent of BMI.
San Francisco American
Association for the
Study of Liver
Diseases
11/05 4.
Is nonalcoholic fatty liver
disease an independent
predictor of the
Metabolic syndrome?
San Francisco American
Association for the
Study of Liver
Diseases
11/05 5.
Hyperinsulinemia is an San Francisco American 11/05 6.
5
independent predictor of
elevated serum ALT levels even
after adjustment to nonalcoholic
fatty liver disease and liver
histology.
Association for the
Study of Liver
Diseases
Serum ALT is not a
reliable screening tool for
nonalcoholic fatty liver
disease in the general
population.
Vienna European
Association for the
Study of the Liver
04/06 7.
Long term nutritional Intake
and the risk for Non-alcoholic
fatty liver disease; A population
based study.
Barcelona European
Association for the
Study of the Liver
04/07 8.
Role of physical activity in non-
alcoholic fatty liver disease
(NAFLD): A population based
study.
Boston American
Association for the
Study of Liver
Diseases
11/07
9.
A comparison between the
hepatorenal ultrasound index
and steatotest for the non-
invasive quantification of liver
steatosis
Milan European
Association for the
Study of the Liver
04/08 10.
Can serum leptin and
adiponectin predict liver injury
in patients with NAFLD? A
study in the general population
Copenhagen European
Association for the
Study of the Liver
04/09 11.
Discordance between three
successive Fibroscan
measurements mirrors the
Copenhagen European
Association for the
Study of the Liver
04/09 12.
6
variability of liver fibrosis
Effect of diet, exercise and anti-
obesity drugs on non-alcoholic
fatty liver disease. Invited
speaker and participant in a
panel discussion
Bologna European
Association for the
Study of the Liver
09/09 13.
A comparison of fatty liver
index with three non-invasive
methods for the detection and
Quantification of liver steatosis:
Regular ultrasound, hepatorenal
ultrasound index and steatotest
Vienna European
Association for the
Study of the Liver
*04/10 14.
The hepatorenal ultrasound
index is correlated with obesity,
ALT, insulin and
adipocytokines
Vienna European
Association for the
Study of the Liver
*04/10 15.
Case study: lifestylie
modification in a patient with
fatty liver.
Invited speaker.
Torino European
Association for the
Study of the Liver
Clinical School of
Hepatology:
Metabolic Liver
Diseases
*05/10 16.
Comparison of FibroTest to
other calculated scores for liver
fibrosis as a screening for
advanced nafld in the general
population.
Nice European
Association for the
Study of the Liver
*01/11
Is there an association between
coffee consumption and
NAFLD or presumed NASH
Nice European
Association for the
Study of the Liver
*01/11
7
and fibrosis in a general adult
population?
Incidence and regression rates
of NAFLD in seven years
follow up of a cohort from the
general population.
Berlin European
Association for the
Study of the Liver
*04/11
Metabolic and clinical aspects
of fructose, soft drinks, and
obesity-related disorders.
Invited speaker.
Athens,
Georgia
University of
Georgia global
health symposium
*09/11
Lifestyle and diet: What
evidence for impact on NAFLD
progression?
Invited speaker and a poster
chair.
Stockholm United European
Gastroenterology
Week
*10/11
Israeli Conferences
Role of noninvasive tests in the
classification of nonalcoholic
fatty liver disease
Eilat The Israeli
Association for the
Study of the Liver
12/02 1.
Factors modulating serum
alanine aminotransferase (ALT)
in patients with nonalcoholic
fatty liver disease.
Haifa The Israeli
Gastroenterology
Association
02/03
2.
Double blind randomized,
placebo-control trial of Orlistat,
for the treatment of primary
nonalcoholic fatty liver disease.
Herzliya The Israeli
Gastroenterology
Association
06/04 3.
Double blind randomized,
placebo-control trial of Orlistat,
for the treatment of primary
nonalcoholic fatty liver disease.
Tel-Aviv The Israeli
Association for the
Research and
Treatment of
06/04 4.
8
Obesity
Is NAFLD an independent
predictor of the metabolic
syndrome?
Eilat The Israeli
Association for the
Study of the Liver
02/05 5.
Nonalcoholic fatty liver disease
and hyperinsulinemia are major
determinants of serum ferritin
levels.
Eilat The Israeli
Association for the
Study of the Liver
03/06 6.
Role of physical activity in non-
alcoholic fatty liver disease
(NAFLD): A population based
study.
Tiberias The Israeli
Gastroenterology
Association
12/07 7.
A comparison between the
hepatorenal ultrasound index
and steatotest for the non-
invasive quantification of liver
steatosis
Eilat The Israeli
Association for the
Study of the Liver
03/08 8.
Discordance between three
successive Fibroscan
measurements mirrors the
variability of liver fibrosis
Kfar Blum The Israeli
Association for the
Study of the Liver
03/09 9.
A comparison of fatty liver
index with three non-invasive
methods for the detection and
Quantification of liver steatosis
Kfar Blum The Israeli
Association for the
Study of the Liver
03/10 10.
9
b. Organization of Conferences or Sessions
Subject of Conference/
Role at Conference/
Comments
Place of
Conference
Name of
Conference
Date
Updates in nutrition/
Chairperson and
organizer/ assembling
position statement on
behalf of ATID
Herzliya, Israel The Israeli dietitians
Association – ATID
professional
conference
11/08 1.
Nutritional treatment for
liver diseases/ Chairperson
and organizer
Tel-Aviv,
Israel
Nutrition Medical
Conference
*01/10 2.
Olive Oil and health,
scientific session
Jerusalem,
Israel
International Olive oil
conference
TERRAOLIVO
*05/11 3.
11
7. Invited Addresses
Presentation/Comments Name of Forum Place of
Lecture
Date
Physical activity
and nutrition for the
elderly
Geriatric
Medical
Conference
Tel-Aviv,
Israel
09/00 1.
Biochemical aspects and
pathogenesis of nonalcoholic
fatty liver disease
The Israeli Organization
of Medical Laboratories
Tel-Aviv,
Israel
01/03
2.
Nonalcoholic fatty liver
disease- a new old disease
Nutrition Medical
Conference
Tel-Aviv,
Israel
02/03 3.
Nonalcoholic fatty liver
disease
The Israeli family
physicians association
conference
Eilat, Israel 04/03 4.
Nonalcoholic fatty liver
disease in children
A pediatric conference in
the Tel Aviv Sourasky
Medical Center
Tel-Aviv,
Israel
07/03
5.
The epidemiology of
primary nonalcoholic
fatty liver
disease in Israel
The Israeli Association
for the Study of the Liver
Herzliya,
Israel
09/04 6.
The metabolic
syndrome,
MABAT from the liver
Nutrition Medical
Conference
Tel-Aviv,
Israel
01/05 7.
The nutritional
Treatment of
nonalcoholic fatty
liver disease
Nutrition Medical
Conference of Clalit
Health Services
Tel-Aviv,
Israel
11/05 8.
11
Vitamins and minerals Nutrition Medical
Conference
Ramat-
Gan, Israel
02/06 9.
Pediatric
nonalcoholic fatty
liver disease
Nutrition Medical
Conference of Clalit
Health Services
Raanana,
Israel
08/07 10.
Nutritional anagement
In liver diseases
Conference by
"Hets"–The
Israeli association
for patients with
liver diseases
Tel-Aviv,
Israel
11/07 11.
The association between viral
hepatitis B & C and insulin
resistance
Nurses
conference
by "Schering-
Plough"
Tel-Aviv,
Israel
05/08 12.
What's between probiotics and
non-alcoholic fatty liver
disease
Nutrition Medical
Conference
Tel-Aviv,
Israel
05/08 13.
The association between egg
consumption and
cardiovascular disease -
Evidence Based Medicine
Nutrition Medical
Conference
Herzliya,
Israel
11/08 14.
The association between
soft drinks and fructose
consumption and obesity,
fatty liver and diabetes
Nutrition Medical
Conference of Clalit
Health Services
Raanana,
Israel
05/09 15.
Effect of diet, exercise
and anti-obesity drugs on
non-alcoholic fatty liver
disease
The Israeli Association
for the Study of the Liver
Ramat-
Gan, Israel
09/09 16.
Update in diet and physical
activity for the treatment of
NAFLD
Tel-Aviv, Israel Nutrition
Medical
Conference
*01/10 17.
12
Nutrition in viral liver
disease and cirrhosis
Nutrition Medical
Conference of Carmel
Hospital
Haifa,
Israel
*02/10 18.
Effect of olive oil in the
liver
International Olive oil
conference
TERRAOLIVO
Jerusalem,
Israel
*05/11 19.
8. Colloquium Talks
Presentation/Comments Name of Forum Place of
Lecture
Date
Clinical and
nutritional aspects of
nonalcoholic
fatty liver disease
Dept. of Nursing, Tel
Aviv University
Tel-Aviv,
Israel
11/02 1.
Case studies in nonalcoholic
fatty liver disease
Maccabi Healthcare
course for Family
Physicians
Ramat-
Gan,
Israel
06/04
2.
Nutritional management in
nonalcoholic fatty liver disease
Nutrition trainee's course,
National Training Center,
Ministry of Health
Tel-
Hashomer,
Israel
05/06 3.
Nutritional treatment for
cirrhosis
Nutrition seminar of
Clalit Health Services
Tel-Aviv,
Israel
10/08 4.
Nutrition in the
Pathogenesis and
treatment of nonalcoholic
fatty liver disease
A conference for
physicians from eastern
Europe at the Tel Aviv
Sourasky medical center
Tel-Aviv,
Israel
12/08 5.
The association between
soft drinks and fructose
consumption and obesity,
fatty liver and diabetes
Nutrition Medical
Conference of Clalit
Health Services
Raanana,
Israel
05/09 6.
13
Nutrition in the
pathogenesis and
treatment of nonalcoholic
fatty liver disease
Gastroenterology course
for medical students at
the Tel-Aviv University
(the 4 years program)
Tel-Aviv,
Israel
*03/10 7.
Nutrition in the
Pathogenesis and
treatment of nonalcoholic
fatty liver disease
A conference for
physicians from
Kazakhstan at the Tel
Aviv Sourasky medical
center
Tel-Aviv,
Israel
*07/10 8.
Role of nutrition in liver
Andcardiovascular
diseases
Nutrition seminar of
Maccabi Healthcare
Ramat-
Hasharon,
Israel
*07/10 9.
Nutrition and obesity in
view of public health and
primary prevention
Health promotion course
for 6th
year medical
students at the Tel-Aviv
University
Tel-Aviv,
Israel
*10/10 10.
Nutrition in the
pathogenesis and
treatment of nonalcoholic
fatty liver disease
Gastroenterology course
for medical students at
the Tel-Aviv University
(the 4 years program)
Tel-Aviv,
Israel
*03/11 11.
9. Research Grants
a. Grants Awarded
In all grants awarded the entire fund amount was assigned to me.
Year Funded by Topic Co-Researchers Role in
Research
2002
Tnuva Research
Fund.
000000 NIS
The association between
calcium intake and the
metabolic syndrome
Prof. Ran Oren Co-PI
2002 Research fund
of the Institute
for the Research
The Prevalence of
primary nonalcoholic
fatty liver disease in the
Prof. Ran Oren PI
14
of the Influence
of Food on
Human Health
and Quality of
Life.
200000 NIS
Israeli population and the
association with
biochemical and
anthropometric
measures.
Papers: See publication
number 2
2002 Chief Scientist
Office, Ministry
of Health,
feasibility study.
25,000 NIS
The association between
treatment with drugs
inhibiting the renin–
angiotensin (RAS)
system and the rate of
non-alcoholic fatty liver
disease in type-2 diabetic
patients
Prof. Ran Oren
Dr. Hanny Yeshua
*Co-PI
2000 Pfizer research
grant.
10,000 NIS
Screening policy for
cardiovascular disease in
Israel: should Non-HDL
cholesterol be routinely
included in risk
assessment and in the
indications for medical
treatment?
Dr. Hanny Yeshua
Samah Haiek
*PI
2011 Pfizer research
grant.
10,000 NIS
Trends in serum
25(OH)D distribution in
the Israeli population in
the last decade
Prof. Tamar Shohat *PI
b. Submission of Research Proposals – Pending
Year Funded by Topic Co-Researchers Role in
Research
2000 Deutsche
Forschungsgemei
nschaft Trilateral
Projects
Ethnic and clinical
differences in Non-
alcoholic fatty liver
disease (NAFLD): A
prospective study in three
diverse populations
Dr. Oren Shibolet
Prof. Ziad Abdeen Prof. Manfred Green
Prof. Michael Manns Prof. Heiner
Wedemeyer
*PI
2011 Italy-Israel
Cooperation
Scientific grant
Association among
Advanced Glycation End
Products, Cytokines and
dietary habits in patients
with non-alcoholic fatty
liver disease
Prof. Fabio Galvano *Co-PI
15
c. Submission of Research Proposals – Not Funded
Score Year Funded by Topic Co-Researchers Role in
Research
- 2010 Pre-
proposal for
the Middle
East
Regional
Cooperation
Program
(MERC).
598,000 $
Detection and treatment
of non-alcoholic fatty
liver disease as a means
of controlling the
epidemic of diabetes
mellitus in the Israeli
and Palestinian
populations
Dr. Arafeh Nabil
Dr. Raed Titi
Prof. Manfred Green
Prof. Ran Oren
*PI
- 2000 Pre-
proposal for
the
MINERVA
Center.
€150,000
per year
Establishment of a
center on biological,
clinical and public
health aspects of liver
diseases and obesity
Prof. Manfred
Green
Prof. Heiner
Wedemeyer
Prof. Ran Oren
*Co-PI
- 2010 Pfizer
research
grant.
10,000 NIS
Building evidence to
public health policy
aimed at reduction of
soft drinks consumption
Hala Nseir
Dr. Assy Nimer
*PI
- 2010 Research
fund of the
Institute for
the
Research of
the
Influence of
Food on
Human
Health and
Quality of
Life.
200000 NIS
Fatty
liver, adipocytokines an
d nutrition in the
prediction of metabolic
disorders incidence in
the general Israeli
population
Prof. Ran Oren
Roni Lotan
*PI
- 2010 Dr. Sima
Lior Fund.
0000000
NIS
The Role of resistance
training in non
alcoholic fatty liver
disease, randomized
clinical trial
Prof. Ran Oren *Co-PI
- 2000 Chief
Scientist
Office,
Ministry of
Health.
0060710
The influence of soft
drinks on serum levels
of Advanced Glycation
End Products and
metabolic and
inflammatory markers
Dr. Assy Nimer *Co-PI
16
NIS in patients with non-
alcoholic fatty liver
- 2010 Chief
Scientist
Office,
Ministry of
Health,
feasibility
study.
000000 NIS
The Role of resistance
training in non
alcoholic fatty liver
disease, randomized
clinical trial
Prof. Ran Oren *Co-PI
- 2010 Clalit
Health
Services
research
fund.
130,000
NIS.
The prevalence of
primary nonalcoholic
fatty liver disease in
low socio-economic
Israeli population, and
the association with
obesity, nutritional
intake and susceptibility
to diabetes
Prof. Ran Oren and
Dr. Hanny Yeshua
*Co-PI
- 2011 The Israel
National
Institute for
Health
Policy and
Health
Services
Research.
150,000
NIS
Trends in serum
25(OH)D distribution in
the Israeli population in
the last decade
Prof. Manfred
Green
*PI
- 2011 Israel
Ministry of
Defence
grant
Non alcoholic fatty
liver disease (NAFLD)
as predictor of diabetes
mellitus, cardiovascular
disease and advanced
liver disease in staff
members of the Israeli
army- long term
prospective follow-up
Dr. Oren Shibolet *PI
17
10. Scholarships, Awards and Prizes
2007 Young investigator award for the best poster, The European Association
for the Study of the Liver. 700 Euro.
11. Teaching
a. Courses Taught in Recent Years
Number of
Students
Degree
B.A./M.A./M.Sc/Ph.D.
Type of Course
Lecture/Seminar/Work
shop
Name of
Course
Year
80 B.A Workshop Nutrition in liver
diseases
2006-
50 None (Ridman" natural
medicine college)
Lectures Medical
nutrition
2007-
2009
8 M.A./M.Sc/Ph.D. Lectures Meta analysis 2008-
20 M.A./M.Sc/Ph.D. Lectures Making sense of
data
2009-
23 M.A./M.Sc/Ph.D. Lectures Nutritional
Epidemiology
2009-
30 M.A./M.Sc/Ph.D. Lectures Construction of
a research
proposal
2009-
10 M.A./M.Sc/Ph.D. Lectures Epidemiology of
cardiovascular
2010-
18
disease
8 M.A./M.Sc/Ph.D. Lectures Applied
research
2010-
b. Supervision of Graduate Students
Student's
Achievements
Date of
Completion /
in Progress
Degree Title of Thesis Name of
Student
- in Progress M.Sc
Incidence of nonalcoholic fatty liver
disease (NAFLD) and
the metabolic syndrome components, a
follow up study
Lotan
Roni*
- in Progress M.Sc
The association between adenomas
and NAFLD
Phlis
Naumi*
- in Progress M.Sc
Physical activity as a treatment for
NAFLD
Buch
Assaf*
- in Progress M.Sc
The association between serum
vitamin D, NAFLD and prediabetes
Edelman
Elena
- in Progress M.Sc
The influence of soft drinks on serum
levels of Advanced Glycation End
Products (AGEs) and metabolic and
inflammatory parameters in patients
with NAFLD
Nseir Hala
- in Progress M.Sc
Knowledge attitudes and practice of
NAFLD patients with
regard to lifestyle modification as
compared to diabetic patients
Dror-Lavi
Gali
- in Progress M.Sc Factors associated with adherence to Ben Abu
19
weight reduction and physical
activity program in obese children
Maya
- in Progress M.Sc
Exposure to passive smoking among
Arab women with acute MI as
compared to controls
Awawdi
Khaled†
- in Progress M.Sc
The association between viral
hepatitis and the metabolic syndrome
Yair-Sabag
Shira
in Progress M.Sc
The association between soft drinks
consumption, serum uric acid and
fatty liver
Openhaimer
Libi
in Progress M.Sc
Knowledge, attitudes and practice
towards soft drinks consumption
among adult Arab population
Jamal
Asuan
in Progress M.Sc
Knowledge, attitudes and
perceptions towards soft drinks
consumption among adult and
pediatric Arab population,
a qualitative research
Abed Petra
90 Graduated MD
research
adviser
Investigating the association between
Hepato-renal index (HRI) and
anthropometric and biochemical
measures among patients of the Fatty
liver clinic
Isaak
Winocur
Michal
*The co-supervisor is Prof. Ran Oren
† The co-supervisor is Prof. Manfred Green
12. Miscellaneous
None
21
PUBLICATIONS
Note: For joint publications, the order of the listed authors appears according to
their relative contribution.
A. Ph.D. Dissertation
Title:
The prevalence of primary nonalcoholic fatty liver disease (NAFLD) in
Israeli population, and the association with biochemical, anthropometric
and nutritional measures.
Date: May 2007
No of pages: 168
Language: English
University: Sackler School of Medicine, Tel Aviv University.
Names of supervisors (Ph.D):
Prof Ran Oren, M.D. Sackler School of Medicine, Tel Aviv University.
Prof Zamir Halpern, M.D. Sackler School of Medicine,
Tel Aviv University.
Dorit Nizan Kaluski, M.D., MPH, R.D. Sackler School of Medicine, Tel
Aviv University.
See publication list: 2, 4, 5, 8.
B. Scientific Books (Refereed)
None
21
C. Monographs - None
D. Articles in Refereed Journals
Published
1. Zelber-Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y, Santo, M.,
Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2006). A double-blind
randomized placebo-controlled trial of Orlistat for the treatment of nonalcoholic
fatty liver disease. Clinical Gastroenterology and Hepatology. (4) 639-44.
IF 5.465
2. Zelber-Sagi, S., Nitzan-Kaluski, D., Halpern, Z., Oren, R. (2006).
Prevalence of primary NAFLD in a population-based study and its association
with biochemical and anthropometric measures. Liver International. (26) 856-
63. IF 2.559
3. Kariv, R., Leshno, M., Beth-Or, A., Strul, H., Blendis, L., Kokia, E., Noff, D.,
Zelber-Sagi, S., Sheinberg, B. Oren, R., Halpern, Z. (2006). Re-evaluation of
serum alanine aminotransferase upper normal limit and its modulating factors in
a large-scale population study. Liver International. (26) 445–50.
IF 2.559
4. Zelber-Sagi, S., Nitzan-Kaluski, D., Halpern, Z., Oren, R. (2007).
NAFLD and serum insulin are major determinants of serum ferritin levels.
Journal of Hepatology. (46) 700-7.
IF 6.642
Received an editorial: Trombini, P., Piperno, A. Ferritin, metabolic syndrome
and NAFLD: Elective attractions and dangerous liaisons. (2007) Journal of
Hepatology. (46) 549-52.
22
5. Zelber-Sagi, S., Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, L.,
Halpern, Z., Oren, R. (2007). The association between NAFLD and long term
nutritional intake, a population based study. Journal of Hepatology. (47) 711-7.
IF 6.642
6. Lurie, Y., Landau, DA., Kanevsky, A., Pel, S., Zelber-Sagi, S., Oren, R. (2007).
Medex test, a novel modality for liver disease diagnosis: a pilot study. Journal of
Clinical Gastroenterology. (41) 700-5.
IF 0.916
7. Lurie, Y., Landau, DA., Blendis, L., Baruch, Y., Veitsman, E., Ackermann, Z.,
Zelber-Sagi, S., Halpern, Z., Oren, R. (2007). Acute hepatitis C in Israel: a
predominantly iatrogenic disease? Journal of Gastroenterology and Hepatology.
(22) 158-64.
IF 0.983
8. Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Zvibel, I.,
Goldiner, I., Blendis, L., Halpern, Z., Oren, R. (2008). Role of leisure-time
physical activity in non-alcoholic fatty liver disease (NAFLD): A population
based study. Hepatology. (48) 1791-8.
IF 10.734
9. Webb, M., Yeshua, H., Zelber-Sagi, S.*, Santo, M., Brazowski, E., Halpern, Z.,
Oren, R. (2009). The Diagnostic Value of a Computerized Hepatorenal Index for
Ultrasonographic Quantification of Liver Steatosis. American Journal of
Roentgenology. (192) 909-14.
IF 2.47
*The second and third authors contributed equally to the paper.
23
10. *Ratziu, V., Zelber-Sagi, S. (2009). Pharmacologic therapy of non-alcoholic
steatohepatitis. Review. Clinics in Liver Disease. (13) 667-88.
11. *Zelber-Sagi, S., Ratziu, V., Oren, R. (2011). Nutrition and physical activity in
NAFLD – an overview of the epidemiological evidence. Review. World Journal
of Gastroenterology. (17) 3377-89.
IF 2.24
Received a "Topic highlight":
Nimer, A. (2011). Nutritional recommendations for patients with non-alcoholic
fatty liver disease. World Journal of Gastroenterology. (17) 3375–6.
12. *Zelber-Sagi, S., Yeshua H., Shlomai A., Blendis L., Leshno M., Levit S.,
Halpern Z., Oren R. (2011). Sampling variability of transient elastography
according to probe location. European Journal of Gastroenterology &
Hepatology. (23) 507-14.
IF 1.598
13. *Maharshak N., Halfon P., Deutsch V., Peretz H., Berliner S., Fishman S.,
Zelber-Sagi, S., Rozovski U., Leshno M., Oren R. (2011). Increased fibrosis
progression rates in hepatitis C patients who carry the PTG20210A mutation.
World Journal of Gastroenterology. (17) 5007-13.
IF 2.24
Accepted for Publication
14. *Zelber-Sagi S., Lotan R., Shlomai A., Webb M., Harrari G., Buch A., Nitzan-
Kaluski D., Halpern Z., Oren R. (2011). Predictors for incidence and remission of
NAFLD in the general population during a seven-year prospective follow-up.
Journal of Hepatology.
24
*The first and the second authors contributed equally to the paper.
IF 9.334
15. *Zelber-Sagi S., Ratziu V., Zvibel I., Goldiner I., Blendis L., Morali G., Halpern
Z., Oren R (2011). Can serum leptin and adiponectin predict liver injury in
NAFLD? A study in the general population. European Journal of
Gastroenterology & Hepatology.
IF 1.598
16. *Salamone, F., Volti, GL., Titta, L., Barbagallo, I., Puzzo, L., Zelber-Sagi, S.,
Pelicci, PG., Giorgio, M., Galvano, F. (2011). Moro orange juice prevents fatty
liver in mice. World Journal of Gastroenterology.
IF 2.24
E. Articles or Chapters in Scientific Books
(which are not Conference Proceedings)
None
F. Articles in Conference Proceedings - None
G. Entries in Encyclopedias - None
H. Other Scientific Publications
25
Published
Abstracts Papers Presented at Scientific Meetings, published as
1. Zelber-Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y, Santo, M.,
Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2004). A double-blind
randomized placebo-controlled trial of Orlistat for the treatment of nonalcoholic
fatty liver disease. Hepatology. (40) 1069.
2. Zelber-Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y, Santo, M.,
Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2005). Does weight loss improve
liver histopathology in patients with NAFLD? Journal of Hepatology. Sup. (42)
705.
3. Kessler, A., Levy, Y., Roth, A., Zelber-Sagi, S., Leshno, M., Blendis,
L.,Halpern, Z., Oren, R. (2005).
Increased prevalence of NAFLD in patients with acute myocardial infarction
independent of BMI. Hepatology (42) 1084.
4. Zelber-Sagi, S., Nitzan-Kalusky, D., Halpern, Z., Oren, R. (2005).
Is NAFLD an independent predictor of the metabolic syndrome?
Hepatology (42) 1069.
5. Zelber-Sagi, S., Nitzan-Kalusky, D., Halpern, Z., Oren, R. (2005).
Hyperinsulinemia is an independent predictor of elevated serum ALT levels
even after adjustment to NAFLD and liver histology. Hepatology (42) 1081.
6. Zelber-Sagi, S., Nitzan-Kalusky, D., Halpern, Z., Oren, R. (2006).
Serum ALT is not a reliable screening tool for NAFLD in the general
population. Journal of Hepatology. Sup. 2(44) 727.
7. Zelber-Sagi, S., Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, M.,
Halpern, Z., Oren, R. (2007). The association between NAFLD and long term
26
nutritional intake, a population based study. Journal of Hepatology. Sup. 1(46)
291.
8. Zelber-Sagi, S., Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, M.,
Halpern, Z., Oren, R. (2007). Role of physical activity in non-alcoholic fatty
liver disease (NAFLD): A population based study. Hepatology (46) 1150.
9. *Zelber-Sagi, S., Webb, M., Ratziu, V., Poynard, T., Halpern, Z., Oren, R.
(2008). A comparison between the hepatorenal ultrasound index and steatotest
for the non-invasive quantification of liver steatosis. Journal of Hepatology.
Sup. 2(48) 368.
10. Zelber-Sagi, S., Yeshua, H., Halpern, Z., Oren, R. (2009).
Discordance between three successive Fibroscan measurements mirrors the
variability of liver fibrosis. Journal of Hepatology. Sup. 1(50) 375.
11. Zelber-Sagi, S., Ratziu, V., Zvibel, I., Goldiner, I., Nitzan-Kaluski , D., Blendis,
L., Gilles, M., Halpern, Z., Oren, R. (2009).
Can serum leptin and adiponectin predict liver injury in patients with NAFLD? A
study in the general population. Journal of Hepatology. Sup. 1(50) 375.
12. *Zelber-Sagi, S., Webb, M., Leshno, M., Blendis, L., Yeshua, H., Ratziu, V.,
Halpern, Z., Oren, R. (2010). A comparison of fatty liver index with three non-
invasive methods for the detection and Quantification of liver steatosis: Regular
ultrasound, hepatorenal ultrasound index and steatotest. Journal of Hepatology.
Sup. 1(52) 158.
13. *Zelber-Sagi, S., Webb, M., Leshno, M., Blendis, L., Isaak Winocur, M.,
Yeshua, H., Halpern, Z., Oren, R. (2010). The hepatorenal ultrasound index is
correlated with obesity, ALT, insulin and adipocytokines. Journal of Hepatology.
Sup. 1(52) 158.
27
14. *Zelber-Sagi, S., Lotan, R., Webb, M., Halpern, Z., Oren, R. (2011). Incidence
and regression rates of NAFLD in seven years follow up of a cohort from the
general population. Journal of Hepatology. Sup. 1(54) 351.
I. Other Publications
1. Zelber-Sagi, S., Oren, R. Non alcoholic fatty liver disease – the hepatic
manifestation of the metabolic syndrome. Israeli journal of medicine. 8:25-
30, 2007.
2. Zelber-Sagi, S., Oren, R. Non alcoholic fatty liver disease. In: Liver
diseases. Israel: Prolog publishing 2006.
J. Other Works Connected with my Scholarly Field - None
K. Submitted Publications
1. *Zelber-Sagi S., Webb M., Santo E., Blendis L., Yeshua H., Leshno M., Ratziu V.,
Halpern Z., Oren R. A comparison of fatty liver index with three non-invasive methods
for the detection and Quantification of liver steatosis.
28
L. Summary of my Activities and Future Plans
Field of interest and scientific work so far
My research and publications address a wide spectrum of issues regarding non-alcoholic
fatty liver disease (NAFLD) including its prevalence in the general population,
screening methods, independent risk factors and the dual association with the metabolic
syndrome, biochemical characteristics and the association with nutrition and physical
activity.
1. Demonstrating that NAFLD is a prevalent disease in adult Israeli population
with insulin resistance, abdominal obesity and hypertriglyceridemia as
independent risk factors. These results emphasize the crucial role of central
adiposity and the mandatory use of fat distribution indices in metabolic
disorders. Published.
2. Testing issues dealing with ALT, the most specific liver enzyme, including its
value as a screening tool for NAFLD and elaboration of the ALT-insulin
association found in previous epidemiological studies. ALT was not an effective
marker for NAFLD at the population level. In preparation.
3. Since serum ferritin was suggested as one the components of the metabolic
syndrome and is closely associated with NAFLD, we further elaborated this
association by assembling, for the first time, all three variables into the equation.
According to our results, NAFLD may be considered as a possible mediator
between insulin resistance/ metabolic syndrome and serum ferritin levels.
Published.
4. Publishing one of the first epidemiological studies dealing with the
association of NAFLD with long term nutritional intake. Intake of soft
drinks and protein from all kinds of meat was found to be associated with
increased risk for NAFLD and intake of protein from fish rich in omega-3
tended to be associated with a reduced risk for NAFLD. Published.
5. Publishing a paper demonstrating that higher leisure-time physical activity
is inversely associated with NAFLD. This association is independent of
HOMA, nutritional intake, adiponectin and resistin and for resistance
physical activity also of BMI. Published.
29
6. Quantification of liver steatosis is clinically relevant in various liver
diseases, but cannot be done by conventional ultrasound, which only
provides a qualitative assessment with significant observer variability. The
aim of our study was to test whether US can serve as an objective tool for the
quantification of hepatic steatosis by comparing computerized liver
echogenicity to that of the right kidney - hepatorenal ultrasound index (HRI).
We showed that HRI is a sensitive, reproducible, operator independent non-
invasive method for steatosis quantification. Published.
Current scientific projects
1. The incidence of nonalcoholic fatty liver disease (NAFLD) and the
metabolic syndrome components. The aim of our study is to describe the
incidence of NAFLD and the metabolic syndrome components, based on a
follow up of a general Israeli population previously screened for NAFLD. In
preparation.
2. Adipocytokines and FibroMax (a set of biochemical markers for liver
steatosis, inflammation and fibrosis). The aim of this study is to evaluate
whether liver injury in NAFLD can be predicted by serum leptin and
adiponectin. Leptin and adiponectin have been implicated in the development of
hepatic steatosis, inflammation and fibrosis in NAFLD. We found that
Adiponectin and leptin are among the variables most strongly associated with
steatosis and NASH but not with fibrosis. Recently accepted for publication.
3. Discordance between three successive Fibroscan measurements mirrors
the sampling variability of liver fibrosis. Transient Elastography (Fibroscan),
a noninvasive technique, can assess liver fibrosis by measuring liver stiffness
from various liver sites and thus helpful in estimating fibrosis variability.
Almost one third of the patients had some level of discordance between the three
successive Fibroscan measurements. Adopting the maximal or the minimal score
may change dramatically the diagnosis.
31
4. A comparison of fatty liver index with three non-invasive methods for the
detection and quantification of liver steatosis: Regular ultrasound,
hepatorenal ultrasound index and steatotest. The paper deals with the
comparison of different screening tools for fatty liver in the general population.
In preparation.
5. The initiation of a randomized clinical trial - Physical activity as a
treatment for nonalcoholic fatty liver (NAFLD). The effect of different
physical activity regimens will be tested in NAFLD patients with regard to liver
enzymes, metabolic status, body composition and steatosis.
6. The initiation of a controlled clinical trial - The influence of soft drinks on
serum levels of Advanced Glycation End Products (AGEs) and metabolic
and inflammatory parameters in patients with Non-Alcoholic Fatty Liver
Disease. Several patients have been recruited.
7. A case-control study- the association between adenomas and nonalcoholic
fatty liver disease (NAFLD). Data collection is preformed prospectively since
June 2010.
8. Data analysis from the CORDIS (cohort of Israeli employees) data-base with
regard to non-HDL cholesterol and cardiovascular mortality and
hepatocellular carcinoma.
9. Vitamin D and metabolic parameters in the Israeli population– initiating a
study in Macabi health services about the association with NAFLD and pre-
diabetes and the effect of supplementation.
10. Re-evaluation of the normal range of vitamin D with historical cohort of
blood donors with cooperation of the ICDC. Initiation, writing grants and
establishing a research team.